John Mantsch
Corporate Officer/Principal en Marquette University .
Perfil
John Mantsch is the founder of Promentis Pharmaceuticals, Inc. which was founded in 2007.
Currently, he is the Chairman of the Biomedical Sciences Department at Marquette University.
Dr. Mantsch completed his undergraduate degree at Allegheny College and his doctorate at Louisiana State University Shreveport.
Cargos activos de John Mantsch
| Empresas | Cargo | Inicio |
|---|---|---|
| Marquette University | Corporate Officer/Principal | - |
Antiguos cargos conocidos de John Mantsch.
| Empresas | Cargo | Fin |
|---|---|---|
Promentis Pharmaceuticals, Inc.
 Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Founder | - |
Formación de John Mantsch.
| Allegheny College | Undergraduate Degree |
| Louisiana State University Shreveport | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Promentis Pharmaceuticals, Inc.
Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |
- Bolsa de valores
- Insiders
- John Mantsch
